Trial Search Results

Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined.

This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Radiation: Fractionated Stereotactic Radiosurgery (SRS)
  • Procedure: Surgical resection





   - Age 18 years and older

   - Pathologically-proven solid tumor malignancy

   - 1 to 4 brain metastases, one of which is 4.2 to 33.5 cm³.

   - Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
   has not previously been treated with SRS.

   - Prior cytotoxic systemic therapy must be completed ≥ 5 days prior to radiosurgery. No
   concurrent cytotoxic systemic therapy along with SRS. Cytotoxic systemic therapy to
   start ≥ 5 days after the completion of SRS.

   - Life expectancy of ≥ 12 weeks.

   - Ability to understand and the willingness to sign a written informed consent.


   - Previously treated with whole brain irradiation

   - Target metastatic lesion previously been treated with SRS.

   - > 4 total brain metastases at the time of initial evaluation.

   - Pregnant

   - Unable to give informed consent.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305